U.S. markets closed
  • S&P Futures

    3,845.00
    -3.25 (-0.08%)
     
  • Dow Futures

    30,993.00
    -20.00 (-0.06%)
     
  • Nasdaq Futures

    11,876.50
    -3.75 (-0.03%)
     
  • Russell 2000 Futures

    1,728.00
    -0.60 (-0.03%)
     
  • Crude Oil

    97.75
    -0.78 (-0.79%)
     
  • Gold

    1,739.20
    +2.70 (+0.16%)
     
  • Silver

    19.12
    -0.04 (-0.20%)
     
  • EUR/USD

    1.0199
    +0.0015 (+0.14%)
     
  • 10-Yr Bond

    2.9130
    +0.1040 (+3.70%)
     
  • Vix

    26.73
    -0.81 (-2.94%)
     
  • GBP/USD

    1.1942
    +0.0020 (+0.17%)
     
  • USD/JPY

    135.6360
    -0.2790 (-0.21%)
     
  • BTC-USD

    20,410.93
    +547.45 (+2.76%)
     
  • CMC Crypto 200

    443.85
    +8.32 (+1.91%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,322.29
    +214.64 (+0.82%)
     

Altimmune to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GAITHERSBURG, Md., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following upcoming virtual investor conferences in October:

  • H.C. Wainwright 4th Annual NASH Investor Conference
    Monday, October 5, 2020 – 3:30 pm ET

  • Guggenheim Securities’ 1st Annual Vaccines & Infectious Diseases Day
    Monday, October 5, 2020 – 4:45 pm ET

The H.C. Wainwright presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events/Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts:

Stacey Jurchison

Ashley R. Robinson

Altimmune, Investor Relations

LifeSci Advisors, LLC

Phone: 410-474-8200

617-430-7577

sjurchison@altimmune.com

arr@lifesciadvisors.com